The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relationship of polymorphism Mad1 1673 G>A on outcomes in patients with advanced ovarian cancer treated with carboplatine-paclitaxel.
M. SantibaƱez
No relevant relationships to disclose
D. Prada
No relevant relationships to disclose
C. Diaz
No relevant relationships to disclose
C. Castro
No relevant relationships to disclose
F. Morales-Vasquez
No relevant relationships to disclose
D. Gallardo Rincon
No relevant relationships to disclose
L. A. Herrera
No relevant relationships to disclose